1. Home
  2. AGIO vs PSEC Comparison

AGIO vs PSEC Comparison

Compare AGIO & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • PSEC
  • Stock Information
  • Founded
  • AGIO 2007
  • PSEC 2004
  • Country
  • AGIO United States
  • PSEC United States
  • Employees
  • AGIO N/A
  • PSEC N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • PSEC Finance/Investors Services
  • Sector
  • AGIO Health Care
  • PSEC Finance
  • Exchange
  • AGIO Nasdaq
  • PSEC Nasdaq
  • Market Cap
  • AGIO 1.4B
  • PSEC 1.3B
  • IPO Year
  • AGIO 2013
  • PSEC 2004
  • Fundamental
  • Price
  • AGIO $38.80
  • PSEC $2.87
  • Analyst Decision
  • AGIO Buy
  • PSEC Sell
  • Analyst Count
  • AGIO 6
  • PSEC 1
  • Target Price
  • AGIO $57.40
  • PSEC $3.00
  • AVG Volume (30 Days)
  • AGIO 976.6K
  • PSEC 4.3M
  • Earning Date
  • AGIO 07-31-2025
  • PSEC 09-05-2025
  • Dividend Yield
  • AGIO N/A
  • PSEC 18.82%
  • EPS Growth
  • AGIO N/A
  • PSEC N/A
  • EPS
  • AGIO 11.13
  • PSEC N/A
  • Revenue
  • AGIO $40,875,000.00
  • PSEC $764,750,000.00
  • Revenue This Year
  • AGIO $18.94
  • PSEC N/A
  • Revenue Next Year
  • AGIO $201.70
  • PSEC N/A
  • P/E Ratio
  • AGIO $3.49
  • PSEC N/A
  • Revenue Growth
  • AGIO 30.57
  • PSEC N/A
  • 52 Week Low
  • AGIO $23.42
  • PSEC $2.73
  • 52 Week High
  • AGIO $62.58
  • PSEC $5.57
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 58.69
  • PSEC 36.34
  • Support Level
  • AGIO $34.71
  • PSEC $2.80
  • Resistance Level
  • AGIO $37.73
  • PSEC $2.89
  • Average True Range (ATR)
  • AGIO 1.50
  • PSEC 0.07
  • MACD
  • AGIO 0.15
  • PSEC 0.01
  • Stochastic Oscillator
  • AGIO 82.21
  • PSEC 73.68

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About PSEC Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Share on Social Networks: